|Bid||109.85 x 300|
|Ask||109.90 x 100|
|Day's Range||109.57 - 110.27|
|52 Week Range||79.12 - 112.97|
|PE Ratio (TTM)||22.13|
|Earnings Date||Jul 25, 2017|
|Dividend & Yield||1.80 (1.64%)|
|1y Target Est||108.35|
Quest Diagnostics (DGX) acquires Med Fusion and Clear Point lab businesses to grow in oncology space.
Weak revenue per requisition performance and reimbursement pressure might dampen Quest Diagnostics' (DGX) benefits from esoteric testing business, infectious disease testing and prescription drug monitoring business growth.
MADISON, N.J. , July 18, 2017 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX) today announced that it has completed its previously announced acquisition of the laboratory businesses Med Fusion and Clear ...